Current and Emerging Drug Treatment Options for Alzheimerʼs Disease

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

(2013) Parminder Raina et al.   ANNALS OF INTERNAL MEDICINE

2011 Alzheimer’s disease facts and figures

(2011)   Alzheimers & Dementia

Revision of the criteria for Alzheimer's disease: A symposium

(2011) Steven T. DeKosky et al.   Alzheimers & Dementia

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

(2011) Paul S. Aisen et al.   Archives of Medical Science

Genetics of Alzheimer's disease: new evidences for an old hypothesis?

(2011) Jean-Charles Lambert et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Plasma β-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease

(2011) Ángela González-Martínez et al.   EXPERIMENTAL GERONTOLOGY

Drug delivery strategies for Alzheimer's disease treatment

(2011) Antonio Di Stefano et al.   Expert Opinion on Drug Delivery

Memantine in dementia: a review of the current evidence

(2011) Nathan Herrmann et al.   EXPERT OPINION ON PHARMACOTHERAPY

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

(2011) Christopher M. Clark   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A phase II trial of huperzine A in mild to moderate Alzheimer disease

(2011) M. S. Rafii et al.   NEUROLOGY

A Single Ascending Dose Study of Bapineuzumab in Patients With Alzheimer Disease

(2010) Ronald S. Black et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study

(2010) Taro Goto et al.   Alzheimers & Dementia

A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients With Alzheimer Disease

(2010) David S. Geldmacher et al.   ARCHIVES OF NEUROLOGY

A Meta-Analysis of Cytokines in Alzheimer's Disease

(2010) Walter Swardfager et al.   BIOLOGICAL PSYCHIATRY

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease

(2010) Jaclyn Cappell et al.   CNS DRUGS

Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease

(2010) Murat Emre et al.   CNS Neuroscience & Therapeutics

High PIB Retention in Alzheimers Disease is an Early Event with Complex Relationship with CSF Biomarkers and Functional Parameters

(2010) A. Forsberg et al.   Current Alzheimer Research

Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

(2010) Michael Gold et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease

(2010) Nazem Bassil et al.   EXPERT OPINION ON PHARMACOTHERAPY

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease

(2010) Joseph F. Quinn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Metabolic Syndrome and Risk of Dementia in Older Adults

(2010) Paola Forti et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

(2010) Juha O Rinne et al.   LANCET NEUROLOGY

Alzheimer's disease: clinical trials and drug development

(2010) Francesca Mangialasche et al.   LANCET NEUROLOGY

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

(2010) Harald Hampel et al.   NATURE REVIEWS DRUG DISCOVERY

The clinical use of structural MRI in Alzheimer disease

(2010) Giovanni B. Frisoni et al.   Nature Reviews Neurology

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

(2010) H. H. Feldman et al.   NEUROLOGY

Neurofibrillary and neurodegenerative pathology in APP-transgenic mice injected with AAV2-mutant TAU: neuroprotective effects of Cerebrolysin

(2009) Kiren Ubhi et al.   ACTA NEUROPATHOLOGICA

NIC5-15 as a treatment for Alzheimer's: Safety, pharmacokinetics and clinical variables

(2009) Hillel Grossman et al.   Alzheimers & Dementia

Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men

(2009) Pamela Garzone et al.   Alzheimers & Dementia

Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers

(2009) Holly Soares et al.   Alzheimers & Dementia

The ADCS valproate neuroprotection trial: Primary efficacy and safety results

(2009) Pierre N. Tariot et al.   Alzheimers & Dementia

GSI-953 is a potent APP-selective gamma-secretase inhibitor for the treatment of Alzheimer's disease

(2009) Steven Jacobsen et al.   Alzheimers & Dementia

Review: Donepezil in Severe Alzheimer's Disease

(2009) Bengt Winblad   American Journal of Alzheimers Disease and Other Dementias

Brief Psychosocial Therapy for the Treatment of Agitation in Alzheimer Disease (The CALM-AD Trial)

(2009) Clive Ballard et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

(2009) Randall J. Bateman et al.   ANNALS OF NEUROLOGY

Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors

(2009) Sudeep S. Gill et al.   ARCHIVES OF INTERNAL MEDICINE

Methylene blue and Alzheimer's disease

(2009) Murat Oz et al.   BIOCHEMICAL PHARMACOLOGY

Nicotinic Receptor-Mediated Neuroprotection in Neurodegenerative Disease Models

(2009) Shun Shimohama   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Meta-Analysis of Alzheimer's Disease Risk with Obesity, Diabetes, and Related Disorders

(2009) Louis A. Profenno et al.   BIOLOGICAL PSYCHIATRY

Rivastigmine Transdermal Patch Skin Tolerability

(2009) Jeffrey L. Cummings et al.   CLINICAL DRUG INVESTIGATION

The Role of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) in Alzheimer’s Disease

(2009) Qingguang Jiang et al.   CNS DRUGS

Novel Regimens and Delivery Systems in the Pharmacological Treatment of Alzheimerʼs Disease

(2009) Nazem Bassil et al.   CNS DRUGS

Natural Non-Trasgenic Animal Models for Research in Alzheimers Disease

(2009) Manuel Sarasa et al.   Current Alzheimer Research

Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer’s Disease: Systematic Review of the ‘Real-World’ Evidence

(2009) I.A. Lockhart et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Memantine in Moderately-Severe-to-Severe Alzheimerʼs Disease

(2009) Francesca Clerici et al.   DRUGS & AGING

Cerebrolysin

(2009) Greg L. Plosker et al.   DRUGS & AGING

Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy

(2009) P. J. Modrego et al.   EUROPEAN JOURNAL OF NEUROLOGY

Cholesterol-modifying strategies for Alzheimer’s disease

(2009) Alina Solomon et al.   Expert Review of Neurotherapeutics

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?

(2009) Pierre N. Tariot et al.   JOURNAL OF CLINICAL PSYCHIATRY

Lithium Trial in Alzheimer's Disease

(2009) Harald Hampel et al.   JOURNAL OF CLINICAL PSYCHIATRY

Green Tea (-)-Epigallocatechin-3-Gallate Inhibits β-Amyloid-Induced Cognitive Dysfunction through Modification of Secretase Activity via Inhibition of ERK and NF-κB Pathways in Mice

(2009) Jae Woong Lee et al.   JOURNAL OF NUTRITION

Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer’s disease: ADAS-cog subscale results from the Alphase study

(2009) D. Saumier et al.   Journal of Nutrition Health & Aging

Development of AFFITOPE vaccines for Alzheimer’s disease (AD) — From concept to clinical testing

(2009) A. Schneeberger et al.   Journal of Nutrition Health & Aging

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study

(2009) Laura Y. Park-Wyllie et al.   PLOS MEDICINE

P4-346: Safety, tolerability and biomarker effects of an Abeta monoclonal antibody administered to patients with Alzheimer's disease

(2008) Eric R. Siemers et al.   Alzheimers & Dementia

P4-351: Effects of uninterrrupted intravenous immunoglobulin treatment of Alzheimer's disease for nine months

(2008) Diamanto Tsakanikas et al.   Alzheimers & Dementia

O3-04-07: Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks

(2008) Claude M. Wischik et al.   Alzheimers & Dementia

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

Green tea epigallocatechin-3-gallate (EGCG) reduces β-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice

(2008) Kavon Rezai-Zadeh et al.   BRAIN RESEARCH

Peroxisome Proliferator-Activated Receptor-γ-Mediated Positive Energy Balance in the Rat Is Associated with Reduced Sympathetic Drive to Adipose Tissues and Thyroid Status

(2008) William T. Festuccia et al.   ENDOCRINOLOGY

Emerging and potential therapies for Alzheimer's disease

(2008) Heledd H Griffiths et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Reassessing the amyloid cascade hypothesis of Alzheimer's disease

(2008) Sanjay W. Pimplikar   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

Etazolate, a neuroprotective drug linking GABAAreceptor pharmacology to amyloid precursor protein processing

(2008) Maryline Marcade et al.   JOURNAL OF NEUROCHEMISTRY

Volumetric MRI and cognitive measures in Alzheimer disease

(2008) B. H. Ridha et al.   JOURNAL OF NEUROLOGY

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

(2008) Rachelle S Doody et al.   LANCET

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

(2008) Gordon K Wilcock et al.   LANCET NEUROLOGY

Evaluation of Dimebon in cellular model of Huntington's disease

(2008) Jun Wu et al.   Molecular Neurodegeneration

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

(2008) Ganesh M Shankar et al.   NATURE MEDICINE

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

(2008) Norman R. Relkin et al.   NEUROBIOLOGY OF AGING

Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta

(2008) John S. K. Kauwe et al.   NEUROGENETICS

Statins, incident Alzheimer disease, change in cognitive function, and neuropathology

(2008) Z. Arvanitakis et al.   NEUROLOGY

Tau-based treatment strategies in neurodegenerative diseases

(2008) Anja Schneider et al.   Neurotherapeutics

PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease

(2008) Gary Landreth et al.   Neurotherapeutics

No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial

(2008) Daniëlle de Jong et al.   PLoS One

The amyloid  -peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae

(2008) C. A. Hansson Petersen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease

(2008) P. Hemachandra Reddy et al.   TRENDS IN MOLECULAR MEDICINE

Efficacy of Memantine on Behavioral and Psychological Symptoms Related to Dementia: A Systematic Meta-Analysis

(2007) Ian D Maidment et al.   ANNALS OF PHARMACOTHERAPY

Galantamine in Alzheimer’s disease

(2007) George Razay et al.   Expert Review of Neurotherapeutics